ZSAN News and Press, Zosano Pharma Corporation From 03/11/21

Zosano Pharma (ZSAN): Q4 GAAP EPS of -$0.08 beats by $0.01.Revenue of $224KCash and cash equivalents of $35.3M.Press Release For further details see: Zosano Pharma EPS beats by $0.01

FREMONT, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2020, as well as business highlights. “Over this pa...

FREMONT, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Life Sciences Con...

Zosano Pharma ([[ZSAN]] +1.3%) has received the official Type A meeting minutes from the U.S. FDA regarding the requirements for resubmission of its Qtrypta (zolmitriptan transdermal microneedle system) New Drug Application ((NDA)) following the Complete Response Letter it received in October...

FREMONT, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company has received the official Type A meeting minutes from the U.S. Food and Drug Administration (“FDA") Division o...

FREMONT, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, developing and commercializing therapies that deliver rapid systemic absorption by leverag...

FREMONT, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its propr...

Zosano Pharma Corporation (ZSAN) Q2 2018 Earnings Conference Call August 09, 2018 4:30 PM ET Executives Carol Lizak - Senior Director and Corporate Controller John Walker - Chief Executive Officer Donald Kellerman - Vice President of Clinical Development & Medical Affairs P...

Zosano Pharma (NASDAQ: ZSAN ): Q2 EPS of -$0.75 More news on: Zosano Pharma, Earnings news and commentary, Healthcare stocks news, , Read more ...

Completed enrollment for our M207-ADAM study with 344 subjects Presented additional analyses from the ZOTRIP pivotal study on pain relief and recurrence at the 2018 American Headache Society (AHS) meeting Published M207 nonclinical data in multiple leading scientific journals ...